# ONPATTRO® (patisiran) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/patisiran

> ONPATTRO® (patisiran), sponsored by ALNYLAM PHARMACEUTICALS, INC. (ALNY), received a complete response letter from the FDA; the decision is dated Oct 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ONPATTRO® (patisiran) |
| Codes |  |
| Sponsor | ALNYLAM PHARMACEUTICALS, INC. (ALNY) https://sec-api.dev/companies/alny/catalysts |
| Indications | [attr amyloidosis with cardiomyopathy](https://sec-api.dev/indications/attr-amyloidosis-with-cardiomyopathy) |
| Modality | sirna |
| FDA designations | orphan |

## Timeline

### September 13, 2023: FDA advisory committee meeting

- Status: completed, positive. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The committee will discuss supplemental new drug application (sNDA) 210922-s015, for ONPATTRO (patisiran) lipid complex for injection, submitted by Alnylam Pharmaceuticals, Inc., for the proposed treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults." https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-september-13-2023-cardiovascular-and-renal-drugs-advisory
- FDA advisory committee calendar: "VOTE: Do patisiran’s benefits outweigh its risks for the treatment of ATTR cardiomyopathy? Provide rationale for your vote. If you voted yes, describe the patient population, the clinically meaningful benefit, and how the clinical meaningfulness was established. If you voted no, provide recommendations for additional data and/or analyses that may support a positive benefit/risk assessment of patisiran for the treatment of ATTR cardiomyopathy Vote Result: Yes: 9 No: 3 Abstain: 0" https://www.fda.gov/media/173671/download

### Oct 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month. Stage: 3.
- First seen 2025-02-13, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001178670-26-000076): "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR-CM, in October 2023, the FDA issued a complete response letter in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm
- SEC Form 10-Q (accession 0001178670-26-000062): "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR-CM, in October 2023, the FDA issued a complete response letter in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-028605): "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR-CM, in October 2023, the FDA issued a CRL in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm
- SEC Form 10-K (accession 0001628280-26-007497): "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR-CM, in October 2023, the FDA issued a CRL in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-047345): "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR amyloidosis with cardiomyopathy, in October 2023, the FDA issued a CRL in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm
- SEC Form 10-Q (accession 0001178670-25-000090): "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR amyloidosis with cardiomyopathy, in October 2023, the FDA issued a CRL in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000090/alny-20250630.htm
- SEC Form 10-Q (accession 0001178670-25-000052): "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR amyloidosis with cardiomyopathy, in October 2023, the FDA issued a CRL in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm
- SEC Form 10-K (accession 0001178670-25-000026): "Despite positive safety and efficacy results from our APOLLO-B clinical trial, in October 2023, the FDA issued a CRL for our sNDA for patisiran for the treatment of ATTR amyloidosis with cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm
- SEC Form 10-K (accession 0001178670-25-000026): "For example, although we reported positive results from the APOLLO-B Phase 3 clinical trial of patisiran in patients with ATTR amyloidosis with cardiomyopathy, in October 2023, the FDA issued a CRL in response to our sNDA for patisiran, indicating the sNDA could not be approved in its present form." https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm

## Same indication

- [Nucresiran](https://sec-api.dev/pdufa/nucresiran) (ALNY)
- [AMVUTTRA® (vutrisiran)](https://sec-api.dev/pdufa/vutrisiran) (ALNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/patisiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ONPATTRO® (patisiran) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/patisiran

```bibtex
@misc{secapidev_pdufa_patisiran_20261116,
  title        = {ONPATTRO® (patisiran) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/patisiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_patisiran_20261116","title":"ONPATTRO® (patisiran) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/patisiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
